Published in Nanomedicine (Lond) on March 01, 2013
Retracted Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection. BMC Cardiovasc Disord (2014) 1.44
Flow cytometry for intracellular SPION quantification: specificity and sensitivity in comparison with spectroscopic methods. Int J Nanomedicine (2015) 0.93
Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors. Int J Nanomedicine (2014) 0.90
Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A (2015) 0.87
Local hyperthermia for esophageal cancer in a rabbit tumor model: Magnetic stent hyperthermia versus magnetic fluid hyperthermia. Oncol Lett (2013) 0.85
Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol (2013) 0.85
Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation. Nano Today (2015) 0.83
Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today (2014) 0.82
High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv (2013) 0.82
Using natural language processing techniques to inform research on nanotechnology. Beilstein J Nanotechnol (2015) 0.80
Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy. J Mater Sci Mater Med (2015) 0.79
Differential stress reaction of human colon cells to oleic-acid-stabilized and unstabilized ultrasmall iron oxide nanoparticles. Int J Nanomedicine (2014) 0.77
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors. J Control Release (2015) 0.77
Nanotechnology applications in thoracic surgery. Eur J Cardiothorac Surg (2016) 0.77
Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy. Nanomedicine (Lond) (2016) 0.75
Fluorescent ampicillin analogues as multifunctional disguising agents against opsonization. Nanoscale (2016) 0.75
Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy. Theranostics (2016) 0.75
Long-term monitoring for nanomedicine implants and drugs. Nat Nanotechnol (2016) 0.75
Near-Infrared Emission CuInS/ZnS Quantum Dots: All-in-One Theranostic Nanomedicines with Intrinsic Fluorescence/Photoacoustic Imaging for Tumor Phototherapy. ACS Nano (2016) 0.75
IgA and IgM protein primarily drive plasma corona-induced adhesion reduction of PLGA nanoparticles in human blood flow. Bioeng Transl Med (2017) 0.75
Composite iron oxide-Prussian blue nanoparticles for magnetically guided T1-weighted magnetic resonance imaging and photothermal therapy of tumors. Int J Nanomedicine (2017) 0.75
Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A (2008) 5.76
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A (2007) 3.23
Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc (2011) 3.19
What the cell "sees" in bionanoscience. J Am Chem Soc (2010) 3.07
Protein-nanoparticle interactions: opportunities and challenges. Chem Rev (2011) 2.34
The evolution of the protein corona around nanoparticles: a test study. ACS Nano (2011) 2.05
Protein-nanoparticle interactions: What does the cell see? Nat Nanotechnol (2009) 2.00
Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc (2008) 1.60
Complete high-density lipoproteins in nanoparticle corona. FEBS J (2009) 1.47
Quantification of nanoparticle uptake by cells using an unbiased sampling method and electron microscopy. Nanomedicine (Lond) (2011) 1.43
The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. Am J Obstet Gynecol (2005) 1.43
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release (2012) 1.41
Exposure assessment: recommendations for nanotechnology-based pesticides. Int J Occup Environ Health (2011) 1.39
Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology (2010) 1.38
Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett (2007) 1.37
Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One (2011) 1.36
Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics. Nanomedicine (2011) 1.35
Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials (2010) 1.34
Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation (2004) 1.31
Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop. J Nanopart Res (2008) 1.28
Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J R Soc Interface (2009) 1.26
Reproducible comet assay of amorphous silica nanoparticles detects no genotoxicity. Nano Lett (2008) 1.25
Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small (2011) 1.25
Time and space resolved uptake study of silica nanoparticles by human cells. Mol Biosyst (2010) 1.25
Fate and effects of CeO2 nanoparticles in aquatic ecotoxicity tests. Environ Sci Technol (2009) 1.20
Nanotoxicology: nanoparticles reconstruct lipids. Nat Nanotechnol (2009) 1.19
Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc (2005) 1.17
Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther (2006) 1.16
Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J (2012) 1.15
Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem Neurosci (2010) 1.14
Nanopesticides: guiding principles for regulatory evaluation of environmental risks. J Agric Food Chem (2014) 1.12
Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. Biomaterials (2006) 1.10
Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far? Ecotoxicology (2012) 1.09
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol (2011) 1.08
Harmonic nanocrystals for biolabeling: a survey of optical properties and biocompatibility. ACS Nano (2012) 1.04
Management of nanomaterials safety in research environment. Part Fibre Toxicol (2010) 1.04
In vitro developmental toxicity test detects inhibition of stem cell differentiation by silica nanoparticles. Toxicol Appl Pharmacol (2009) 1.02
Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making. ACS Nano (2015) 1.01
Use of nanoparticles in Swiss Industry: a targeted survey. Environ Sci Technol (2008) 1.00
Protein fibrillation and nanoparticle interactions: opportunities and challenges. Nanoscale (2013) 1.00
Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology (2015) 0.99
Activation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity. J Nanobiotechnology (2011) 0.97
Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem (2009) 0.96
Nanoscale reference materials for environmental, health and safety measurements: needs, gaps and opportunities. Nanotoxicology (2012) 0.94
Effects of particulate matter on inflammatory markers in the general adult population. Part Fibre Toxicol (2012) 0.94
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem (2010) 0.93
Cationic nanoparticles induce caspase 3-, 7- and 9-mediated cytotoxicity in a human astrocytoma cell line. Nanotoxicology (2010) 0.93
Toxic effects of brake wear particles on epithelial lung cells in vitro. Part Fibre Toxicol (2009) 0.92
Genotoxicity evaluation of amorphous silica nanoparticles of different sizes using the micronucleus and the plasmid lacZ gene mutation assay. Nanotoxicology (2010) 0.91
Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL-6 release. Glia (2002) 0.91
Elution of labile fluorescent dye from nanoparticles during biological use. PLoS One (2011) 0.90
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem (2005) 0.90
Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond) (2012) 0.89
Associations of short-term particle and noise exposures with markers of cardiovascular and respiratory health among highway maintenance workers. Environ Health Perspect (2014) 0.89
Biological impact assessment of nanomaterial used in nanomedicine. introduction to the NanoTEST project. Nanotoxicology (2013) 0.89
Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J Med Chem (2005) 0.89
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) (2006) 0.89
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. J Med Chem (2012) 0.87
Phase behavior of aqueous polyion-surfactant ion complex salts: effects of polyion charge density. J Phys Chem B (2007) 0.87
Rational design of an organometallic glutathione transferase inhibitor. Angew Chem Int Ed Engl (2009) 0.86
Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles. Nanoscale (2013) 0.86
Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem (2008) 0.86
Heregulins implicated in cellular functions other than receptor activation. Mol Cancer Res (2006) 0.85
Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. Inorg Chem (2012) 0.85
Effect of natural organic matter on cerium dioxide nanoparticles settling in model fresh water. Chemosphere (2010) 0.85
Intracellular localisation, geno- and cytotoxic response of polyN-isopropylacrylamide (PNIPAM) nanoparticles to human keratinocyte (HaCaT) and colon cells (SW 480). Toxicol Lett (2010) 0.85
Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur J Pharm Biopharm (2011) 0.85
Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site. Bioorg Med Chem (2008) 0.85
Nanoparticle usage and protection measures in the manufacturing industry--a representative survey. J Occup Environ Hyg (2010) 0.84
Formation and characterization of the nanoparticle-protein corona. Methods Mol Biol (2013) 0.84
Thermoresponsive chlorambucil derivatives for tumour targeting. Angew Chem Int Ed Engl (2011) 0.84
The policy relevance of wear emissions from road transport, now and in the future--an international workshop report and consensus statement. J Air Waste Manag Assoc (2013) 0.84
Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorg Med Chem (2007) 0.83
Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol (2009) 0.83
Short-term increase in particulate matter blunts nocturnal blood pressure dipping and daytime urinary sodium excretion. Hypertension (2012) 0.82
Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine (2012) 0.82
Studies toward new anti-cancer strategies based on alpha-mannosidase inhibition. Chimia (Aarau) (2010) 0.82
Glycosylation pathways as drug targets for cancer: glycosidase inhibitors. Mini Rev Med Chem (2006) 0.82
Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution. ACS Chem Neurosci (2013) 0.82
Is the toxic potential of nanosilver dependent on its size? Part Fibre Toxicol (2014) 0.81
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chemistry (2008) 0.81
Organometallic cages as vehicles for intracellular release of photosensitizers. J Am Chem Soc (2011) 0.81
Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin. Inorg Chem (2007) 0.81
Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. ChemMedChem (2007) 0.81
Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. J Med Chem (2009) 0.81
In vitro assessment of the pulmonary toxicity and gastric availability of lead-rich particles from a lead recycling plant. Environ Sci Technol (2011) 0.81
Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem (2012) 0.80
Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis (2004) 0.80
Cell response to the exposure to chitosan-TPP//alginate nanogels. Biomacromolecules (2011) 0.80
Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials. Expert Opin Ther Targets (2009) 0.80
Residential exposure to drinking water arsenic in Inner Mongolia, China. Toxicol Appl Pharmacol (2007) 0.80
Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies. Biomaterials (2006) 0.80
Covalent cell surface functionalization of human fetal osteoblasts for tissue engineering. Bioconjug Chem (2011) 0.80
The protein corona mediates the impact of nanomaterials and slows amyloid beta fibrillation. Chembiochem (2013) 0.80
Functionalized pyrrolidines inhibit alpha-mannosidase activity and growth of human glioblastoma and melanoma cells. J Med Chem (2005) 0.80